Orchid Cellmark Inc. was founded in 1995 and is headquartered in Princeton, New Jersey. Orchid Cellmark Inc. operates as an international provider of identity DNA testing services for the forensic, immigration, and family relationships markets. The company has laboratories in the United States and the United Kingdom; and offers its services to police forces and other government entities. It also provides non-DNA forensic laboratory services. The company's forensic DNA testing is primarily used to confirm that a suspect committed a particular crime, to exonerate an innocent person, or to establish or maintain databases of individuals convicted of crimes; and family relationship DNA testing is used to establish whether two or more people are genetically related. Its DNA testing is used by individuals and employers in security applications to establish or store a person's genetic profile for identification purposes in the event of an emergency or accident. The company was formerly known as Orchid Biosciences Inc. and changed its name to Orchid Cellmark Inc. in June 2005.

Osiris Therapeutics, Inc. company was founded in 1992 and is headquartered in Columbia, Maryland. Osiris Therapeutics, Inc., a stem cell therapeutic company, develops products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas in the United States. The company's principal product includes Prochymal, which is in phase III clinical trials for the treatment of steroid refractory Graft versus Host Disease (GvHD), acute GvHD, Crohn's disease, and acute radiation syndrome; and in phase II clinical trials for the treatment of Type I diabetes mellitus, acute myocardial infarction, and chronic obstructive pulmonary disease. Its product also consists of Chondrogen, a Phase II clinical trial product for the treatment of osteoarthritis and the reduction of pain in the knee. Osiris Therapeutics has collaboration agreements with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen; Juvenile Diabetes Research Foundation for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes; and JCR Pharmaceuticals Co., Ltd. for distributing Prochymal for the treatment of GvHD in Japan.

Nymox Pharmaceutical was founded in 1989 and is based in St. Laurent, Canada. Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs and diagnostic devices. Its products include NicAlert and TobacAlert tests that use urine or saliva to detect use of and exposure to tobacco products; and AlzheimAlert, a urinary test that aids physicians in the diagnosis of Alzheimer's disease. The company's products under development comprises NX-1207, which is in phase III trial for the treatment of enlarged prostate; NXC-4720, an antibacterial agent that is in laboratory trials for the treatment of E. coli O157:H7 bacterial contamination in hamburger meat, and other food and drink products, as well as for the treatment of urinary tract and other bacterial infections in humans; and Statins, a class of commonly prescribed cholesterol lowering drugs to treat, prevent, or reduce the risk of Alzheimer's disease. It is also in the preclinical stage of developing therapeutic products for oncological indications; and has various diagnostic markers and technologies, including a patented platform for point-of-care testing.

Zila, Inc., a diagnostic company, engages in the prevention, detection, and treatment of oral cancer and periodontal disease. It manufactures and markets ViziLite Plus with TBlue, its flagship product, for early detection of oral abnormalities that could lead to cancer. In addition, the company designs, manufactures, and markets a suite of proprietary products directly to dental professionals for periodontal disease, including the Rotadent Professional Powered Brush, the Pro-Select Platinum ultrasonic scaler, and a portfolio of oral pharmaceutical products for in-office and home-care use. Further, it had certain technology rights, and the United States and foreign patent rights related to the OraTest, an oral cancer diagnostic product. Zila, Inc. markets and sells its products in the United States and Canada through direct sales force, and internationally through third party distributors. The company was founded in 1980 and is headquartered in Phoenix, Arizona. As of September 18, 2009, Zila, Inc. operates as a subsidiary of Tolmar, Inc.

Endocyte, Inc. company was founded in 1996 and is based in West Lafayette, Indiana. Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers.

Genfit SA, a biopharmaceutical company, develops therapies to reduce the cardiometabolic risk. The company focuses on the discovery and development of new chemical entities treating mainly dyslipidemia, atherosclerosis, diabetes, obesity, and inflammatory disorders. It has five programs in clinical phase of which, two are internal projects. The company’s internal projects consist of GFT14 that aims to target one of the major indications of cardiometabolic disease; and GFT505, a multimodal and pluripotent medicine indicated for atherogenic dyslipidemia for a patient who is overweight with or without diabetes. It develops its own drug candidates up to human proof of concept (Phase IIa). Genfit’s pipeline has various modes of action implying multimodal drugs and selective nuclear receptor modulation (SNuRM). The company also establishes partnerships with pharma groups on early-stage drug discovery programs. Its pharma alliances include Merck, Sanofi-Aventis, Solvay, Servier, and Pierre Fabre. Genfit was founded in 1999 and is headquartered in Loos, France with an additional office in Cambridge, the United States.

Fluidigm Corporation was founded as Mycometrix Corporation in 1999 and changed its name to Fluidigm Corporation in June 2001. The company is based in San Francisco, California. Fluidigm Corporation develops and distributes systems based on the properties of integrated fluidic circuits to control precisely fluids on a nano volume scale. The company's product line includes the TOPAZ system, which is used for protein crystallization; and the BioMark system, which is used for genetic analysis.

NicOx S.A. company researches nitric oxide-donating drugs for the treatment of cardiovascular and metabolic ailments, inflammation, and pain. NicOx is researching the combination of nitric oxide with various compounds to treat a variety of diseases, including osteoarthritis, atherosclerosis (vascular inflammation), hypertension, ophthalmic conditions, and respiratory diseases. Its drug development efforts are partially conducted through co-development and licensing agreements with larger drug companies.

Laboratorios Farmacéuticos ROVI manufactures and sells pharmaceuticals in Spain and the rest of Europe. Its best selling prescription drugs include Hibor, (a brand name heparin used to prevent blood clots during surgery), osteoporosis drug Osseor, and angina drug Corlentor. ROVI's handful of OTC products include Autan insect repellant and the Enerzona line of dietary wellness products.In 2009 the company licensed Novavax's VLP vaccine technology which it will use to create a flu vaccine for the Spanish government. The E60 million ($84 million) program is being sponsored by the Spanish Ministry of Health. ROVI was founded in 1946 and went public on the Spanish Stock Exchange in late 2007.

Ceregene is developing gene therapies for a variety of central nervous system disorders. Its pipeline includes two leading candidates in clinical trials: CERE-120 is being investigated for treatment of Parkinson's disease while CERE-110 is being tested on Alzheimer's disease. Both candidates are based upon Ceregene's technology that delivers neurotrophic factors directly into dying neuron cells. The neurotrophic factors are then able to delay the progression of neurodegenerative diseases. Two other candidates are being developed to treat ALS and certain ocular diseases. Genzyme has joined into a partnership to develop and commercialize CERE-120. Additional funding has come from the Michael J. Fox Foundation.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.